{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T23:18:46Z","timestamp":1771888726718,"version":"3.50.1"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001588","name":"Enterprise Ireland","doi-asserted-by":"publisher","award":["CFTD\/2009\/0122"],"award-info":[{"award-number":["CFTD\/2009\/0122"]}],"id":[{"id":"10.13039\/501100001588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001588","name":"Enterprise Ireland","doi-asserted-by":"publisher","award":["CF\/2012\/2608"],"award-info":[{"award-number":["CF\/2012\/2608"]}],"id":[{"id":"10.13039\/501100001588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["822258"],"award-info":[{"award-number":["822258"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/IC\/00051\/2013"],"award-info":[{"award-number":["UID\/IC\/00051\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pulmonary arterial hypertension (PAH) is a progressive disease characterized by increased pulmonary artery pressure leading to right ventricular (RV) failure. While current PAH therapies improve patient outlook, they show limited benefit in attenuating RV dysfunction. Recent investigations demonstrated that the thromboxane (TX) A<jats:sub>2<\/jats:sub> receptor (TP) antagonist <jats:italic>NTP42<\/jats:italic> attenuates experimental PAH across key hemodynamic parameters in the lungs and heart. This study aimed to validate the efficacy of <jats:italic>NTP42:KVA4<\/jats:italic>, a novel oral formulation of <jats:italic>NTP42<\/jats:italic> in clinical development, in preclinical models of PAH while also, critically, investigating its direct effects on RV dysfunction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The effects of <jats:italic>NTP42:KVA4<\/jats:italic> were evaluated in the monocrotaline (MCT) and pulmonary artery banding (PAB) models of PAH and RV dysfunction, respectively, and when compared with leading standard-of-care (SOC) PAH drugs. In addition, the expression of the TP, the target for <jats:italic>NTP42<\/jats:italic>, was investigated in cardiac tissue from several other related disease models, and from subjects with PAH and dilated cardiomyopathy (DCM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the MCT-PAH model, <jats:italic>NTP42:KVA4<\/jats:italic> alleviated disease-induced changes in cardiopulmonary hemodynamics, pulmonary vascular remodeling, inflammation, and fibrosis, to a similar or greater extent than the PAH SOCs tested. In the PAB model, <jats:italic>NTP42:KVA4<\/jats:italic> improved RV geometries and contractility, normalized RV stiffness, and significantly increased RV ejection fraction. In both models, <jats:italic>NTP42:KVA4<\/jats:italic> promoted beneficial RV adaptation, decreasing cellular hypertrophy, and increasing vascularization. Notably, elevated expression of the TP target was observed both in RV tissue from these and related disease models, and in clinical RV specimens of PAH and DCM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study shows that, through antagonism of TP signaling, <jats:italic>NTP42:KVA4<\/jats:italic> attenuates experimental PAH pathophysiology, not only alleviating pulmonary pathologies but also reducing RV remodeling, promoting beneficial hypertrophy, and improving cardiac function. The findings suggest a direct cardioprotective effect for <jats:italic>NTP42:KVA4<\/jats:italic>, and its potential to be a disease-modifying therapy in PAH and other cardiac conditions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.1063967","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T06:37:10Z","timestamp":1670999830000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["The thromboxane receptor antagonist NTP42 promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload"],"prefix":"10.3389","volume":"9","author":[{"given":"Eamon P.","family":"Mulvaney","sequence":"first","affiliation":[]},{"given":"Fabiana","family":"Renzo","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Ad\u00e3o","sequence":"additional","affiliation":[]},{"given":"Emilie","family":"Dupre","sequence":"additional","affiliation":[]},{"given":"Lucia","family":"Bialesova","sequence":"additional","affiliation":[]},{"given":"Viviana","family":"Salvatore","sequence":"additional","affiliation":[]},{"given":"Helen M.","family":"Reid","sequence":"additional","affiliation":[]},{"given":"Gl\u00f3ria","family":"Concei\u00e7\u00e3o","sequence":"additional","affiliation":[]},{"given":"Julien","family":"Grynblat","sequence":"additional","affiliation":[]},{"given":"Aida","family":"Lluci\u00e0-Valldeperas","sequence":"additional","affiliation":[]},{"given":"Jean-Baptiste","family":"Michel","sequence":"additional","affiliation":[]},{"given":"Carmen","family":"Br\u00e1s-Silva","sequence":"additional","affiliation":[]},{"given":"Charles E.","family":"Laurent","sequence":"additional","affiliation":[]},{"given":"Luke S.","family":"Howard","sequence":"additional","affiliation":[]},{"given":"David","family":"Montani","sequence":"additional","affiliation":[]},{"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[]},{"given":"Anton","family":"Vonk Noordegraaf","sequence":"additional","affiliation":[]},{"given":"Fr\u00e9d\u00e9ric","family":"Perros","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Mendes-Ferreira","sequence":"additional","affiliation":[]},{"given":"B. Therese","family":"Kinsella","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCRESAHA.113.301129","article-title":"The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure.","volume":"115","author":"Ryan","year":"2014","journal-title":"Circ Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1183\/09059180.00006511","article-title":"The role of the right ventricle in pulmonary arterial hypertension.","volume":"20","author":"Vonk Noordegraaf","year":"2011","journal-title":"Eur Respir Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1161\/CIRCULATIONAHA.106.632208","article-title":"Right ventricular function and failure: report of a national heart, lung, and blood institute working group on cellular and molecular mechanisms of right heart failure.","volume":"114","author":"Voelkel","year":"2006","journal-title":"Circulation."},{"key":"B4","doi-asserted-by":"publisher","first-page":"D22","DOI":"10.1016\/j.jacc.2013.10.027","article-title":"Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology.","author":"Vonk-Noordegraaf","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019845611","article-title":"Express: right heart in pulmonary hypertension: from adaptation to failure.","volume":"9","author":"Ren","year":"2019","journal-title":"Pulm Circ."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jacc.2018.12.076","article-title":"Anatomy, function, and dysfunction of the right ventricle: jacc state-of-the-art review.","volume":"73","author":"Sanz","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"L443","DOI":"10.1152\/ajplung.00374.2017","article-title":"Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension.","volume":"314","author":"Frump","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1183\/09059180.00007109","article-title":"Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: lessons from the left heart.","volume":"19","author":"Handoko","year":"2010","journal-title":"Eur Respir Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/bph.14866","article-title":"Right heart failure in pulmonary hypertension: diagnosis and new perspectives on vascular and direct right ventricular treatment.","volume":"178","author":"Tello","year":"2021","journal-title":"Br J Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1016\/j.jacc.2011.06.068","article-title":"Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy.","volume":"58","author":"van de Veerdonk","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10555-011-9297-9","article-title":"The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis.","volume":"30","author":"Ekambaram","year":"2011","journal-title":"Cancer Metastasis Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"73171","DOI":"10.18632\/oncotarget.12256","article-title":"Expression of the tpalpha and tpbeta isoforms of the thromboxane prostanoid receptor (Tp) in prostate cancer: clinical significance and diagnostic potential.","volume":"7","author":"Mulvaney","year":"2016","journal-title":"Oncotarget."},{"key":"B13","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1161\/01.CIR.90.6.2952","article-title":"Plasma thromboxane B2 concentration in pulmonary hypertension associated with congenital heart disease.","volume":"90","author":"Fuse","year":"1994","journal-title":"Circulation."},{"key":"B14","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0022-5223(19)36690-5","article-title":"Plasma prostanoids in neonatal extracorporeal membrane oxygenation. Influence of meconium aspiration.","volume":"101","author":"Bui","year":"1991","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B15","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1164\/ajrccm.149.4.8143049","article-title":"Eicosanoids decrease with successful extracorporeal membrane oxygenation therapy in neonatal pulmonary hypertension.","author":"Dobyns","year":"1994","journal-title":"Am J Respir Crit Care Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.","volume":"327","author":"Christman","year":"1992","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1513\/AnnalsATS.201508-543OC","article-title":"Prognostic significance of biomarkers in pulmonary arterial hypertension.","volume":"13","author":"Al-Naamani","year":"2016","journal-title":"Ann Am Thorac Soc."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/sj.bjp.0704416","article-title":"Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the at(1) receptor antagonist losartan.","volume":"134","author":"Katugampola","year":"2001","journal-title":"Br J Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1086\/686140","article-title":"Antagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload.","volume":"6","author":"West","year":"2016","journal-title":"Pulm Circ."},{"key":"B20","first-page":"336","article-title":"Alterations by a thromboxane A2 analog (U46619) of calcium dynamics in isolated rat cardiomyocytes.","volume":"264","author":"Hoffmann","year":"1993","journal-title":"J Pharmacol Exp Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1161\/01.hyp.28.3.444","article-title":"Thromboxane A2 mediates the stimulation of inositol 1,4,5-trisphosphate production and intracellular calcium mobilization by bradykinin in neonatal rat ventricular cardiomyocytes.","volume":"28","author":"Nakamura","year":"1996","journal-title":"Hypertension."},{"key":"B22","doi-asserted-by":"publisher","first-page":"H1353","DOI":"10.1152\/ajpheart.00930.2005","article-title":"Thromboxane A2-induced arrhythmias in the anesthetized rabbit.","volume":"290","author":"Wacker","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1124\/jpet.109.157677","article-title":"Inhibition of thromboxane A2-induced arrhythmias and intracellular calcium changes in cardiac myocytes by blockade of the inositol trisphosphate pathway.","volume":"331","author":"Wacker","year":"2009","journal-title":"J Pharmacol Exp Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1161\/01.HYP.0000112225.27560.24","article-title":"Role for thromboxane receptors in angiotensin-ii-induced hypertension.","volume":"43","author":"Francois","year":"2004","journal-title":"Hypertension."},{"key":"B25","doi-asserted-by":"publisher","first-page":"F1096","DOI":"10.1152\/ajprenal.00369.2007","article-title":"A role for the thromboxane receptor in l-name hypertension.","volume":"295","author":"Francois","year":"2008","journal-title":"Am J Physiol Renal Physiol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011902","article-title":"Antagonism of the thromboxane-prostanoid receptor as a potential therapy for cardiomyopathy of muscular dystrophy.","volume":"8","author":"West","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-1113-2","article-title":"Ntp42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.","volume":"20","author":"Mulvaney","year":"2020","journal-title":"BMC Pulm Med."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173658","article-title":"Efficacy of the thromboxane receptor antagonist Ntp42 Alone, or in combination with sildenafil, in the sugen\/hypoxia-induced model of pulmonary arterial hypertension.","volume":"889","author":"Mulvaney","year":"2020","journal-title":"Eur J Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1161\/CIRCRESAHA.121.319971","article-title":"The Latest in animal models of pulmonary hypertension and right ventricular failure.","volume":"130","author":"Boucherat","year":"2022","journal-title":"Circ Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"L363","DOI":"10.1152\/ajplung.00212.2011","article-title":"The monocrotaline model of pulmonary hypertension in perspective.","volume":"302","author":"Gomez-Arroyo","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3293584","article-title":"Effect of riociguat and sildenafil on right heart remodeling and function in pressure overload induced model of pulmonary arterial banding.","volume":"2018","author":"Rai","year":"2018","journal-title":"Biomed Res Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1093\/eurheartj\/ehac389","article-title":"Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemodynamic trial.","volume":"43","author":"Dachs","year":"2022","journal-title":"Eur Heart J."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204610","article-title":"Pulmonary hypertension-targeted therapies in heart failure: a systematic review and meta-analysis.","volume":"13","author":"Guay","year":"2018","journal-title":"PLoS One."},{"key":"B34","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/phar.2314","article-title":"Efficacy and safety of the use of pulmonary arterial hypertension pharmacotherapy in patients with pulmonary hypertension secondary to left heart disease: a systematic review.","volume":"39","author":"Kido","year":"2019","journal-title":"Pharmacotherapy."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.002636","article-title":"Right ventricular myocardial stiffness in experimental pulmonary arterial hypertension: relative contribution of fibrosis and myofibril stiffness.","volume":"9","author":"Rain","year":"2016","journal-title":"Circ Heart Fail."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000716","article-title":"Protein changes contributing to right ventricular cardiomyocyte diastolic dysfunction in pulmonary arterial hypertension.","volume":"3","author":"Rain","year":"2014","journal-title":"J Am Heart Assoc."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/978-94-007-2888-2_52","article-title":"Remodeling of calcium handling in human heart failure.","volume":"740","author":"Lou","year":"2012","journal-title":"Adv Exp Med Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jss.2012.04.066","article-title":"Differential calcium handling in two canine models of right ventricular pressure overload.","volume":"178","author":"Moon","year":"2012","journal-title":"J Surg Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/s0008-6363(03)00429-2","article-title":"Transgenic rat hearts overexpressing serca2a show improved contractility under baseline conditions and pressure overload.","volume":"59","author":"Muller","year":"2003","journal-title":"Cardiovasc Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/s0008-6363(01)00489-8","article-title":"Reduced level of serine(16) phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced serca2 activity.","volume":"53","author":"Sande","year":"2002","journal-title":"Cardiovasc Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"33984","DOI":"10.1074\/jbc.M114.602581","article-title":"Molecular basis of calpain cleavage and inactivation of the sodium-calcium exchanger 1 in heart failure.","volume":"289","author":"Wanichawan","year":"2014","journal-title":"J Biol Chem."},{"key":"B42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.yjmcc.2017.11.014","article-title":"Hax-1 regulates serca2a oxidation and degradation.","volume":"114","author":"Bidwell","year":"2018","journal-title":"J Mol Cell Cardiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"H128","DOI":"10.1152\/ajpheart.00739.2005","article-title":"Ischemia-reperfusion-induced calpain activation and serca2a degradation are attenuated by exercise training and calpain inhibition.","volume":"290","author":"French","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/cvr\/cvz207","article-title":"Myocardial Mmp-2 contributes to serca2a proteolysis during cardiac ischaemia-reperfusion injury.","volume":"116","author":"Roczkowsky","year":"2020","journal-title":"Cardiovasc Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1164\/rccm.201806-1160ST","article-title":"Assessment of right ventricular function in the research setting: knowledge gaps and pathways forward. an official american thoracic society research statement.","volume":"198","author":"Lahm","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jacbts.2020.07.011","article-title":"Treatment targets for right ventricular dysfunction in pulmonary arterial hypertension.","volume":"5","author":"Prisco","year":"2020","journal-title":"JACC Basic Transl Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1513\/AnnalsATS.201312-425FR","article-title":"Treatment for pulmonary arterial hypertension-associated right ventricular dysfunction.","volume":"11","author":"Gomez-Arroyo","year":"2014","journal-title":"Ann Am Thorac Soc."},{"key":"B48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/rccm.202201-0095LE","article-title":"Inhaled iloprost improves right ventricular load-independent contractility in pulmonary hypertension.","volume":"206","author":"Tello","year":"2022","journal-title":"Am J Respir Crit Care Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"34A","DOI":"10.1016\/s0002-9149(99)80381-6","article-title":"Safety and efficacy of epoprostenol in patients with severe congestive heart failure. epoprostenol multicenter research group.","volume":"75","author":"Sueta","year":"1995","journal-title":"Am J Cardiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/s0002-8703(97)70105-4","article-title":"A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the flolan international randomized survival trial (First).","volume":"134","author":"Califf","year":"1997","journal-title":"Am Heart J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1161\/CIRCRESAHA.111.300448","article-title":"Endothelin axis is upregulated in human and rat right ventricular hypertrophy.","volume":"112","author":"Nagendran","year":"2013","journal-title":"Circ Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000107791","article-title":"Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension\u2013a multi-center randomized study.","volume":"109","author":"Kaluski","year":"2008","journal-title":"Cardiology."},{"key":"B53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/s0167-5273(02)00182-1","article-title":"Do results of the enable (endothelin antagonist bosentan for lowering cardiac events in heart failure) study spell the end for non-selective endothelin antagonism in heart failure?","volume":"85","author":"Kalra","year":"2002","journal-title":"Int J Cardiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0140-6736(04)16723-8","article-title":"Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the endothelina receptor antagonist trial in heart failure (earth): randomised, double-blind, placebo-controlled trial.","volume":"364","author":"Anand","year":"2004","journal-title":"Lancet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1378\/chest.06-1263","article-title":"Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients.","volume":"132","author":"Gan","year":"2007","journal-title":"Chest."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA."},{"key":"B57","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase iib double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation."},{"key":"B58","first-page":"789","article-title":"The platelet thromboxane inhibitor, dazmegrel, does not reduce monocrotaline-induced pulmonary hypertension.","volume":"133","author":"Langleben","year":"1986","journal-title":"Am Rev Respir Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1440-1843.1997.tb00090.x","article-title":"Thromboxane inhibition and monocrotaline-induced pulmonary hypertension in rats.","volume":"2","author":"Nagata","year":"1997","journal-title":"Respirology."},{"key":"B60","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1152\/japplphysiol.00148.2020","article-title":"Pulmonary artery banding is a relevant model to study the right ventricular remodeling and dysfunction that occurs in pulmonary arterial hypertension.","volume":"129","author":"Akazawa","year":"2020","journal-title":"J Appl Physiol."},{"key":"B61","article-title":"US PTO (Patent No. 10,357,504, Fully Granted July 23, 2019)","author":"Kinsella","year":"2019","journal-title":"Thromboxane Receptor Antagonists"},{"key":"B62","article-title":"US PTO (Patent No. 9,932,304, Fully Granted April 3, 2018)","author":"Kinsella","year":"2018","journal-title":"Thromboxane Receptor Antagonists"},{"key":"B63","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1042\/bst0290641","article-title":"Thromboxane A2 signalling in humans: a \u2018Tail\u2019 of two receptors.","author":"Kinsella","year":"2001","journal-title":"Biochem Soc Trans."},{"key":"B64","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/sj.bjp.0705277","article-title":"Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery.","volume":"139","author":"Pauvert","year":"2003","journal-title":"Br J Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1254\/fpj.114.supplement_22","article-title":"The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (Pde) type 5.","volume":"114","author":"Wallis","year":"1999","journal-title":"Nihon Yakurigaku Zasshi."},{"key":"B66","year":"2013","journal-title":"Assessment Report for Opsumit (International Non-Proprietary Name: Macitentan)."},{"key":"B67","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1124\/jpet.108.142976","article-title":"Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist.","volume":"327","author":"Iglarz","year":"2008","journal-title":"J Pharmacol Exp Ther."},{"key":"B68","year":"2016","journal-title":"Assessment Report for Uptravi (International Non-Proprietary Name: Selexipag)."},{"key":"B69","year":"2014","journal-title":"Assessment Report for Adempas (International Non-Proprietary Name: Riociguat)."},{"key":"B70","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","article-title":"Discovery of the soluble guanylate cyclase stimulator vericiguat (bay 1021189) for the treatment of chronic heart failure.","volume":"60","author":"Follmann","year":"2017","journal-title":"J Med Chem."},{"key":"B71","doi-asserted-by":"publisher","first-page":"A824","DOI":"10.1161\/res.125.suppl_1.824","article-title":"Abstract 824: thromboxane\/prostanoid receptor activation increases calpain-mediated proteolysis and alters calcium handling and fibrosis following right ventricular pressure overload.","volume":"125","author":"West","year":"2019","journal-title":"Circulation Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"A443","DOI":"10.1161\/res.127.suppl_1.443","article-title":"Abstract 443: blockade of the thromboxane\/prostanoid receptor prevents Ecg abnormalities in Rv pressure overload.","author":"Carrier","year":"2020","journal-title":"Circulation Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"A261","DOI":"10.1161\/res.123.suppl_1.261","article-title":"Abstract 261: activation of the thromboxane\/prostanoid receptor contributes to elevated end-diastolic calcium in cardiomyocytes and cardiac fibrosis following right ventricular pressure overload.","volume":"123","author":"Carrier","year":"2018","journal-title":"Circulation Res."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.121806","article-title":"Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension.","volume":"143","author":"Langleben","year":"2002","journal-title":"Am Heart J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bcpt.12544","article-title":"Mechanisms involved in thromboxane A2 -induced vasoconstriction of rat intracavernous small penile arteries.","volume":"119","author":"Grann","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/01.RES.0000095245.97945.FE","article-title":"Thromboxane A2-induced inhibition of voltage-gated K+ channels and pulmonary vasoconstriction: role of protein kinase czeta.","volume":"93","author":"Cogolludo","year":"2003","journal-title":"Circ Res."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2020.106476","article-title":"Mechanism of thromboxane receptor-induced vasoconstriction in human saphenous vein.","volume":"151","author":"Ozen","year":"2020","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"B78","first-page":"921","article-title":"Role of extracellular Ca++ Influx Via L-Type and Non-L-Type Ca++ channels in thromboxane A2 RECEPTOR-MEDIATED CONTRACTION IN RAT AORTA.","volume":"284","author":"Tosun","year":"1998","journal-title":"J Pharmacol Exp Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.bpj.2020.08.001","article-title":"Ca(2+) release Via Ip3 receptors shapes the cardiac Ca(2+) transient for hypertrophic signaling.","volume":"119","author":"Hunt","year":"2020","journal-title":"Biophys J."},{"key":"B80","doi-asserted-by":"publisher","first-page":"H1701","DOI":"10.1152\/ajpheart.00470.2010","article-title":"Activation of Nfatc1 is directly mediated by ip3 in adult cardiac myocytes.","volume":"299","author":"Rinne","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1161\/CIRCRESAHA.110.220038","article-title":"The Ip3 receptor regulates cardiac hypertrophy in response to select stimuli.","volume":"107","author":"Nakayama","year":"2010","journal-title":"Circ Res."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2009.02.005","article-title":"Endothelin-1-stimulated insp3-induced ca2+ release is a nexus for hypertrophic signaling in cardiac myocytes.","volume":"33","author":"Higazi","year":"2009","journal-title":"Mol Cell."},{"key":"B83","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/cvr\/cvs236","article-title":"Cooperation between proteolytic systems in cardiomyocyte recycling.","volume":"96","author":"Yamaguchi","year":"2012","journal-title":"Cardiovasc Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1124\/jpet.105.093898","article-title":"Dominant role for calpain in thromboxane-induced neuromicrovascular endothelial cytotoxicity.","volume":"316","author":"Quiniou","year":"2006","journal-title":"J Pharmacol Exp Ther."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11010-005-1370-7","article-title":"Calpain-1-sensitive myofibrillar proteins of the human myocardium.","volume":"278","author":"Barta","year":"2005","journal-title":"Mol Cell Biochem."},{"key":"B86","doi-asserted-by":"publisher","first-page":"12100","DOI":"10.1073\/pnas.95.21.12100","article-title":"Role of calpain in skeletal-muscle protein degradation.","volume":"95","author":"Huang","year":"1998","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B87","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.2527\/1991.69114449x","article-title":"Degradation of myofibrillar proteins by extractable lysosomal enzymes and M-calpain, and the effects of zinc chloride.","volume":"69","author":"Whipple","year":"1991","journal-title":"J Anim Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1161\/01.cir.97.16.1536","article-title":"Elevated levels of 8-Iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure.","volume":"97","author":"Mallat","year":"1998","journal-title":"Circulation."},{"key":"B89","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.cardiores.2007.03.029","article-title":"Sense and Stretchability: the role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction.","volume":"77","author":"Linke","year":"2008","journal-title":"Cardiovasc Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1161\/CIRCRESAHA.109.198465","article-title":"Pkc phosphorylation of Titin\u2019s pevk element: a novel and conserved pathway for modulating myocardial stiffness.","volume":"105","author":"Hidalgo","year":"2009","journal-title":"Circ Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1161\/CIRCRESAHA.111.246819","article-title":"Hyperphosphorylation of mouse cardiac titin contributes to transverse aortic constriction-induced diastolic dysfunction.","volume":"109","author":"Hudson","year":"2011","journal-title":"Circ Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1161\/01.res.0000021115.24712.99","article-title":"Protein kinase a phosphorylates Titin\u2019s cardiac-specific N2b domain and reduces passive tension in rat cardiac myocytes.","volume":"90","author":"Yamasaki","year":"2002","journal-title":"Circ Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"H1618","DOI":"10.1152\/ajpheart.01192.2003","article-title":"Effects of anesthetics on systemic hemodynamics in mice.","volume":"287","author":"Janssen","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s10741-022-10229-7","article-title":"The right ventricular involvement in dilated cardiomyopathy: prevalence and prognostic implications of the often-neglected child.","volume":"27","author":"Manca","year":"2022","journal-title":"Heart Fail Rev."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3791\/60427","article-title":"In Vitro assessment of cardiac function using skinned cardiomyocytes","volume":"160","author":"Gon\u00e7alves-Rodrigues","year":"2020","journal-title":"J Vis Exp"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1063967\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T06:37:23Z","timestamp":1670999843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1063967\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":95,"alternative-id":["10.3389\/fcvm.2022.1063967"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.1063967","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"article-number":"1063967"}}